Survodutide: What to Know About Boehringer's Glucagon Weight-Loss Drug

If you have been following the GLP-1 pipeline, survodutide is the drug that keeps showing up in headlines without ever quite winning one. It is not the biggest number. It is not the newest mechanism. It has not been filed with the FDA. And yet Boehringer Ingelheim keeps investing in it, and the FDA gave it breakthrough therapy designation for liver disease.

That combination confuses a lot of people. This article explains what survodutide is, what its trials actually found, why the weight-loss number is lower than you might expect, and what has to happen before anyone in the United States can get a prescription.

What is survodutide?

Survodutide, also called BI 456906, is an investigational once-weekly injection being developed by Boehringer Ingelheim in partnership with Zealand Pharma [1]. It is a dual glucagon and GLP-1 receptor agonist. That means one molecule switches on two different receptors.

Here is how it fits next to the drugs you already know:

• Semaglutide (Ozempic, Wegovy, Rybelsus) activates GLP-1 only.
• Tirzepatide (Mounjaro, Zepbound) activates GIP and GLP-1.
• Survodutide activates glucagon and GLP-1.
• Retatrutide, still investigational, activates GIP, GLP-1 and glucagon.

The glucagon piece is the interesting part. Glucagon is best known as the hormone that raises blood sugar, which sounds like the last thing you would want in a diabetes or obesity drug. But glucagon also increases how much energy the body burns and pushes the liver to break down stored fat. When it is paired with GLP-1, which lowers blood sugar and reduces appetite, the blood-sugar effect is offset and what is left is the energy-burning and liver effects.

That design choice explains almost everything about survodutide’s results.

What did the SYNCHRONIZE trials show?

SYNCHRONIZE is the name of survodutide’s Phase 3 program. The main trials have all finished.

SYNCHRONIZE-1 (NCT06066515) was the pivotal obesity trial: 726 adults with overweight or obesity and no diabetes, treated for 76 weeks, with primary completion in December 2025 [3]. Boehringer Ingelheim reported average weight loss of up to 16.6% on the efficacy estimand, compared with 3.2% for placebo. At the top dose that worked out to as much as 39.2 pounds (17.8 kg) lost from baseline [1].

A prespecified MRI substudy of 25 participants per arm added the numbers that made people pay attention: at the 6.0 mg dose, a 34.0% reduction in visceral fat (the deep abdominal fat wrapped around organs) versus 11.8% on placebo, and a 63.1% reduction in liver fat versus 24.5% on placebo, with limited loss of lean mass [2][11].

Two things are worth flagging about those figures. They come from a substudy of 25 people per group, not the full 726, so they are directionally striking but statistically fragile. And the headline 16.6% is the efficacy estimand; on the treatment-regimen estimand, which counts everyone randomized, weight loss was 13.0% at 6.0 mg and 12.2% at 3.6 mg versus 5.4% on placebo [11].

The obesity results were published in the New England Journal of Medicine in September 2026 [11], and the SYNCHRONIZE-MASLD liver results appeared in Nature Medicine [2].

SYNCHRONIZE-2 (NCT06066528) ran the same design in 755 adults who also had type 2 diabetes, finishing December 2025 [4].

SYNCHRONIZE-MASLD (NCT06309992) enrolled 218 people with obesity and confirmed or presumed fatty liver disease, with liver fat and weight as endpoints [6].

SYNCHRONIZE-CVOT (NCT06077864) is the big one: 5,531 people, testing cardiovascular safety. It reached primary completion on June 1, 2026, and results had not been published as of September 14, 2026 [5]. That trial matters more than the obesity numbers, because a clean or positive cardiovascular result is what lets a drug claim heart benefits on its label, and heart-benefit claims are what open up insurance coverage.

There were also regional trials in Japan (NCT06176365) and China (NCT06214741), both completed.

Why is survodutide’s weight loss lower than Zepbound or Wegovy HD?

Because it is measuring something slightly different, and because glucagon is not primarily an appetite drug.

For context, here are 2026’s landmark numbers, all from separate trials with different designs and populations:

Drug	Trial	Average weight loss	Duration
Retatrutide 12 mg	TRIUMPH-1	28.3% (efficacy estimand)	80 weeks
CagriSema	REDEFINE 1	22.7% (efficacy estimand)	68 weeks
Semaglutide 7.2 mg (Wegovy HD)	STEP UP	20.7%	72 weeks
Survodutide	SYNCHRONIZE-1	up to 16.6% (efficacy estimand)	76 weeks

Two warnings about that table. First, none of these are head-to-head comparisons. Different trials enroll different people, use different starting weights, and handle dropouts differently. Second, all of those are efficacy-estimand numbers, which describe what happened among people who stayed on the drug as directed. The treatment-regimen numbers, which count everyone regardless of whether they stopped, are always lower.

So survodutide sits in the lower half of the late-stage pack on total weight lost. What it does not sit low on is metabolic organ effects. A 63% cut in liver fat is a large effect, and visceral fat is the fat most strongly linked to metabolic disease. Whether that translates into better long-term health outcomes than a drug that removes more total pounds is exactly what the outcomes trials are supposed to answer.

What are survodutide’s side effects?

The trials reported the pattern you would expect from this class: nausea, vomiting, diarrhea and constipation, mostly during dose escalation.

The full SYNCHRONIZE-1 results are now published in the New England Journal of Medicine, which puts hard numbers on the tolerability question [11]. Gastrointestinal adverse events, typically mild to moderate, occurred in:

Group	Participants with a gastrointestinal adverse event
Survodutide 3.6 mg	80.9%
Survodutide 6.0 mg	89.7%
Placebo	47.9%

Those are high rates, and they are the clearest signal in the trial that survodutide’s glucagon activity carries a gastrointestinal cost. No deaths were reported [11].

A separate and more specific figure has circulated in secondary coverage: a gastrointestinal discontinuation rate near 19% [2]. We are still marking that number as reported rather than confirmed. The NEJM paper describes discontinuation of the trial regimen by a substantial proportion of participants as a study limitation, but we could not confirm the specific 19% figure against the published tables.

The distinction matters. An 80% to 90% rate of having a gastrointestinal symptom is not the same as an 80% to 90% rate of stopping the drug — most of these events were mild to moderate and concentrated during dose escalation. The number that determines whether a drug is usable in practice is the discontinuation rate, and that is the one still not pinned down.

As always, side-effect information here describes what the trials reported. It is not advice about whether any drug is right for you. That is a conversation with a healthcare provider.

Why does survodutide have FDA breakthrough therapy designation?

The FDA granted survodutide breakthrough therapy designation in MASH (metabolic dysfunction-associated steatohepatitis) in 2024 [1]. MASH is fatty liver disease that has progressed to inflammation and scarring, and it is a serious condition with very few treatment options.

Breakthrough therapy designation is worth understanding because it gets misread constantly. It means the FDA has agreed that a drug treats a serious condition and that early evidence suggests a substantial improvement over what is available. It buys the company more intensive FDA guidance and eligibility for faster review paths. It does not mean the drug works, does not mean it will be approved, and does not shorten the trials themselves.

Survodutide’s liver trials are enormous and slow:

• LIVERAGE (NCT06632444): 1,800 people with MASH and moderate or advanced fibrosis, recruiting, primary completion December 27, 2031 [7].
• LIVERAGE-Cirrhosis (NCT06632457): 1,590 people with MASH and cirrhosis, recruiting, primary completion June 5, 2029 [8].

Those dates tell you that the liver indication, the one with the breakthrough designation, is the slowest part of the program, not the fastest.

When could survodutide be approved in the United States?

There is no announced filing date and no announced launch date.

Here is what is knowable. The core SYNCHRONIZE obesity program finished in December 2025. The cardiovascular safety trial finished in June 2026. Both of those are the pieces a company normally needs before submitting an obesity application. If Boehringer Ingelheim files on that package, a standard FDA review of 10 to 12 months would put a decision somewhere in 2027 or 2028.

That is an estimate, not company guidance. Boehringer Ingelheim has not published a US submission date. Some secondary analysis has modeled a 2027 US launch, but treat modeled launch dates from market-research firms as guesses, not schedules.

It is also worth noting what Boehringer Ingelheim keeps investing in. In 2026 the company opened a brand-new Phase 3 trial in type 2 diabetes (NCT07754461, 600 people, recruiting, primary completion January 2028) and has a Phase 2 kidney study planned [9]. Companies do not start new Phase 3 trials for drugs they are abandoning. But those new trials also will not read out until 2028, which stretches the full label out for years.

Which survodutide trials are still open?

This is the practical question for most readers, because in the United States a trial is the only legal way to receive an unapproved drug outside a narrow expanded-access route.

As of September 14, 2026, these survodutide studies were listed as recruiting or opening:

• LIVERAGE (NCT06632444), MASH with moderate or advanced fibrosis, 1,800 participants
• LIVERAGE-Cirrhosis (NCT06632457), MASH with cirrhosis, 1,590 participants
• Type 2 diabetes glycemic control (NCT07754461), 600 participants
• Albuminuria reduction in kidney disease (NCT07206290), Phase 2, 120 participants, not yet recruiting

Note what is missing from that list: an obesity trial. The SYNCHRONIZE obesity studies are all closed. If your only qualifying condition is obesity, there is currently no survodutide obesity trial to join.

The two LIVERAGE trials are the big open doors, and they require a MASH diagnosis with a specific fibrosis stage. Screening typically involves specialized imaging such as FibroScan or MRI-PDFF, and sometimes a liver biopsy. That is a real commitment, and it is not something to sign up for casually.

To look for sites, search the NCT numbers above at ClinicalTrials.gov, or use Boehringer Ingelheim’s own trial finder at trials.boehringer-ingelheim.com [10]. Bring the informed consent document to your own healthcare provider before you decide.

Can you buy survodutide online?

No, not legitimately, and this is worth being blunt about.

Survodutide is not approved in any country. That means there is no legal manufacturer selling it to patients anywhere in the world. Every vial sold online under the name “survodutide,” including anything labeled “research use only” or “not for human consumption,” is an unapproved product made outside the regulated supply chain. Nobody has verified its identity, purity, sterility, or how much active ingredient is actually in the vial.

The FDA has publicly warned about unapproved GLP-1 products sold for weight loss, including reports of dosing errors and adverse events. The same warning applies with more force to a drug that has no approved version anywhere for comparison.

The legal routes to survodutide in the United States are: a clinical trial, or nothing.

What should you take away from survodutide?

Three things.

First, it is a liver and metabolic drug that also causes weight loss, not a weight-loss drug that happens to help the liver. Reading its results through the lens of “how does it compare to Zepbound on pounds” misses the point of the molecule.

Second, tolerability is its real risk. The published trial shows gastrointestinal adverse events in 81% to 90% of people on survodutide versus 48% on placebo [11]. The specific discontinuation rate is the number still to watch when any FDA review documents become public.

Third, it is further from your pharmacy than the headlines suggest. No filing has been announced, the liver indication does not finish its pivotal trials until 2029 and 2031, and the newest diabetes trial does not complete until 2028.

If you are managing weight or metabolic disease now, survodutide is not a plan. The approved options and the drugs currently under FDA review are. Talk to a healthcare provider about what fits your situation.

Sources

1. Boehringer Ingelheim, “Results of the Phase III SYNCHRONIZE-1 obesity trial” — https://www.boehringer-ingelheim.com/us/human-health/metabolic-diseases/results-phase-iii-synchronize-1-obesity-trial
2. AJMC, “Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss” — https://www.ajmc.com/view/survodutide-phase-3-data-signal-metabolic-gains-beyond-weight-loss
3. ClinicalTrials.gov, NCT06066515 (SYNCHRONIZE-1) — https://clinicaltrials.gov/study/NCT06066515
4. ClinicalTrials.gov, NCT06066528 (SYNCHRONIZE-2) — https://clinicaltrials.gov/study/NCT06066528
5. ClinicalTrials.gov, NCT06077864 (SYNCHRONIZE-CVOT) — https://clinicaltrials.gov/study/NCT06077864
6. ClinicalTrials.gov, NCT06309992 (SYNCHRONIZE-MASLD) — https://clinicaltrials.gov/study/NCT06309992
7. ClinicalTrials.gov, NCT06632444 (LIVERAGE) — https://clinicaltrials.gov/study/NCT06632444
8. ClinicalTrials.gov, NCT06632457 (LIVERAGE-Cirrhosis) — https://clinicaltrials.gov/study/NCT06632457
9. ClinicalTrials.gov, NCT07754461 (type 2 diabetes Phase 3) — https://clinicaltrials.gov/study/NCT07754461
10. Boehringer Ingelheim clinical trial finder — https://www.trials.boehringer-ingelheim.com/
11. le Roux CW, et al., “Survodutide Once Weekly for the Treatment of Adults with Obesity” (SYNCHRONIZE-1), New England Journal of Medicine, 2026 — https://www.nejm.org/doi/full/10.1056/NEJMoa2600751